Lupin sells US Commercial Women's Health Specialty Business

A global pharmaceutical company, Lupin Ltd has recently confirmed that it has sold its US commercial women’s health specialty business to a US biopharmaceutical company, Evofem Biosciences, Inc. that focuses entirely on women’s health.

Founded in 2015, Evofem Biosciences, Inc. is commercial-stage biopharmaceutical company that caters in the Biotechnology Research industry with headquarters in San Diego, California. The company is dedicated towards developing in addition to commercializing innovative products, intending to address unmet needs of women's sexual and reproductive health.

US commercial women’s health specialty business of Lupin is dedicated towards selling SOLOSEC (secnidazole) 2g oral granules which is a FDA-approved single-dose antibiotic drug, offering bacterial vaginosis’ (BV) and trichomoniasis’ full treatment regimen which are 2 common sexual health illnesses.

The firm may receive a total payment of up to $84 million based on future dependent milestones, as per the agreement terms.

Dr Fabrice Egros, President of Global Corporate Development at Lupin said, “We are very pleased to divest our US commercial women’s health specialty business, including SOLOSEC, to Evofem. This disposal is another step towards aligning our US specialist company with our strategy plan to grow our specialty business in therapeutic areas with synergistic building blocks. These include respiratory and neurological disorders.”